​​​​​​​Patients as Partners Europe

It is essential to understand how patient involvement in clinical research can accelerate medicine development, how it can improve better access, inclusivity and diversity. The medicine development community is figuring out how patient data is being used and must find solutions to return data back to patients. The R&D industry is also grappling with an understanding of how patient involvement can help advance sustainable clinical development? It is important to demonstrate the value of patient engagement in clinical trials and to know what’s on the regulatory landscape.

Experts from Sanofi, GSK, Boehringer Ingelheim, Lundbeck, Novartis, Pfizer, Ipsen, AstraZeneca, Roche and more gathered with patient advocacy to address:

​​​​​​•  ​​​​​​​The future of patient informed research
•  Understanding patient preferences and decentralized clinical trials
•  Advancing health equity and diversifying clinical trials to engage underserved communities
•  The patient experience data landscape and returning patient data
•  Turning patient insights into action
•  Mapping and how to measure patient engagement
•  Patient burden-reducing solutions and technologies
•  Regulatory requirements and patient engagement in drug development

The 8th annual #PatientsEU2024 conference offered an unparalleled opportunity to hear from pharma R&D and patient advocacy together on how patient involvement gets done to drive greater efficiencies in clinical research with better outcomes. The conference prioritized the patient voice for the R&D industry to learn how we can move into the next phase of patient centricity to better support access and decision-making for patients, increase diverse representation to connect with a wide range of patient communities, and how this transformation will make finding clinical research easier for patients and allow for faster and more efficient clinical development.